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Abstract
Purpose: The purpose of this study was to evaluate the orally administered combination of flavonoids desmin
and troxerutin with Centella asiatica and Melilotus for the treatment of diabetic cystoid macular edema (CME)
without macular thickening.
Methods: In this prospective, interventional, controlled study, 40 consecutive patients with type 2 diabetes and
CME without macular thickening at optical coherence tomography were randomized into 2 groups of 20 subjects
each (treatment and control groups). The treatment group received an oral combination of desmin (300mg/day)
and troxerutin (300mg/day) with C. asiatica (30mg/die) andMelilotus (160mg/die) for 14 months. Best collected
visual acuity, central retinal thickness at optical coherence tomography, retinal sensitivity (RS), and stability of
fixation at microperimetry were measured at baseline and monthly for 14 months.
Results: In both groups, mean best collected visual acuity, central retinal thickness, and stability of fixation did
not show differences during follow-up (P> 0.05). At month 14, the RS was greater in the treated group (P¼ 0.01)
and was significantly reduced in the control group only (P< 0.001). Five eyes in the study group showed
disappearance of the intraretinal cysts after a mean time of 3.5 0.3 months, which persisted in the following
months. These 5 eyes presented a greater RS at each follow-up visit when compared with the control group
(P< 0.05). Anatomic improvement was never reported in the control group.
Conclusions: The orally administered combination of flavonoids, C. asiatica, and Melilotus could be beneficial in
preserving RS in diabetic CME without macular thickening.
Introduction
Diabetic macular edema is one of the main causes ofvisual impairment and legal blindness in patients with
diabetic retinopathy.1 Presence of cystoid macular edema
(CME) without macular thickening at optical coherence to-
mography (OCT) has been recently reported in diabetic pa-
tients as a newly emerging OCT-defined entity.2 Flavonoids
are polyphenolic compounds with a wide distribution
throughout the plant kingdom and potent anti-inflammatory
properties. The prospective, controlled, multicentric RELIEF
(Reflux assEssment and quaLity of lIfe improvEment with
micronized Flavonoids) study included 5,052 patients in 23
countries and showed that the use of micronized, purified
flavonoid fraction can reduce symptoms of pain, heaviness,
and edema in patients with venous reflux.3,4 Troxerutin has
been shown to reduce expression of vascular endothelial
growth factor in experimental models because of its anti-
oxidant properties.5 Centella asiatica decreases endothelial
permeability and capillary filtration and is active in diabetic
microangiopathy.6 The oral administration of alphatoco-
pherol, rutin, Melilotus officinalis, and C. asiatica has been
shown to reduce sovrafascial edema in patients with chronic
venous insufficiency.7 Herein, we evaluated the orally ad-
ministered combination of flavonoids desmin and troxerutin
with C. asiatica and Melilotus for the treatment of diabetic
CME without retinal thickening.
Methods
In this prospective, interventional, controlled study, 40
consecutive patients with type 2 diabetes and CME without
macular thickening at OCT were randomized into 2 groups
of 20 subjects each (treatment and control groups). Informed
consent was obtained from all the patients. The study
was approved by the eye clinic’s ethics committee at the
Eye Department, University Federico II, Naples, Italy.
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University Federico II of Naples and was performed in ac-
cordance with the ethical standards laid down in the 1964
Declaration of Helsinki. Inclusion criteria were absence of
clinically significant macular edema at clinical examination,
presence of nonischemic CME, normal central retinal thick-
ness (CRT) and normal foveal contour at OCT examination,
and absence of any previous treatment for diabetic retinop-
athy in the 6 months preceding first examination. Exclusion
criteria were coexisting ocular pathologies and significant
media opacities that precluded fundus examination.
In the treatment group, an oral combination of desmin
(300mg/day) and troxerutin (300mg/day) with C. asiatica
(30mg/day) and Melilotus (160mg/day) was administered
for 14 months.
All patients included in the study were evaluated at
baseline and monthly for 12 months. At each visit, investi-
gations included best corrected visual acuity (BCVA) after
refraction using the ETDRS letters scale, slit-lamp examina-
tion, funduscopy and stereofundus photography, OCT, and
central microperimetry (MP). Fluorescein angiography was
performed at baseline to exclude ischemic macular edema.
Mean value of glycosylated hemoglobin (HbA1c) and blood
pressure were monitored at baseline and every 3 months.
Normal HbA1c values were considered to be between 4%
and 6%. Blood hypertension was classified as normal tension
(<120/80), prehypertension (120–139/80–89), stage 1 (140–
159 systolic or 90–99 diastolic), and stage 2 (160 systolic or
100 diastolic).8
To evaluate CRT, a spectral domain scanning laser
ophthalmoscope/OCT device (SD-SLO/OCT; Ophthalmic
Technologies, Toronto, Canada) was used. CRT was con-
sidered as the thickness in the central 1-mm disc, re-
presenting the foveal area. An upper limit of 280 mm for
normal CRT was chosen according to the previously re-
ported normal retinal thickness values as measured with SD-
SLO/OCT.9 Normal foveal contour was determined by the
presence of a well-formed U-shaped foveal depression
without marked steepening, flattening, or asymmetry. In-
traretinal cysts were identified as well-circumscribed hy-
poreflective spaces within the fovea, measuring at least
10 mm in diameter.2 Fundus-related MP was performed using
the SD-SLO/OCT. A 4-2-1 double staircase strategy was
used and results were reported in decibels. The recorded
fixation pattern was classified according to the Fujii classifi-
cation.10 Retinal sensitivity in the 88 central area and stability
of fixation were measured at each visit.
Statistical analysis was performed using the Statistical
Package for Social Sciences (version 17.0; SPSS, Chicago, IL).
Intragroup changes were compared by repeated measures
analysis of variance with Dunnett correction for multiple
Table 1. Characteristics of 40 Patients Presenting with Cystoid Macular Edema
Without Macular Thickening at Baseline, Who Were Randomized into 2 Groups (Control Group
and Group Treated with Flavonoids, Centella asiatica, and Melilotus)
Treatment group Control group Statistical difference
Patients, n (eyes) 20 (20) 20 (20) —
Duration of diabetes (mean SD), years 6.4 4.1 6.2 4.6 P¼ 0.1
%HbA1c (mean SD, range) 7.2 1.8 (5.1–12.0) 7.4 1.3 (5.5–10.6) P¼ 0.2
% HbA1c of the last 5 years (mean SD) 7.0 2.1 6.7 1.5 P¼ 0.1
Hypertension stage
Stage 1 no. (%) 10 (50) 8 (40) P¼ 0.1
Stage 2 no. (%) 5 (25) 6 (30) —
Prehypertension no. (%) 5 (25) 6 (30) —
Microalbuminuria (mean SD), mg/L 4.12 3.1 4.18 3.6 P¼ 0.1
SD, standard deviation; HbA1c, glycosylated hemoglobin.
FIG. 1. Diabetic CME without macular thickening treated with an orally administered combination of flavonoids, Centella
asiatica, and Melilotus. At baseline, (a) intraretinal cystoid spaces without macular thickening are visible on optical coherence
tomography examination. (b) After 6 months of treatment, a complete resolution of the cystoid edema is evident and (c) an
improvement of retinal sensitivity is present at differential microperimetry. In another case, the optical coherence tomog-
raphy scans show (d) the CME without macular thickening at baseline, (e) the resolution of the CME after 6 months of
treatment, and (f ) the improvement of retinal sensitivity as measured with differential microperimetry. CME, cystoid
macular edema.
110 FORTE ET AL.
comparisons. Fisher’s exact test was used to compare the
retinal sensitivity (RS) between eyes that showed an ana-
tomical improvement and the control group at each follow-
up visit. Results were considered significant if the P value
was <0.05. Data at baseline, month 3, month 6, and month 14
are presented.
Results
In the treatment group, the 20 patients (9 women and 11
men; 20 eyes) had a mean age of 63.6 3.1 years. In the
control group, the 20 patients (9 women and 11 men; 20 eyes)
had a mean age of 62.2 3.4 years. The characteristics of the
40 patients in the 2 groups at baseline are given in Table 1.
No differences were present at baseline between the 2 groups
with respect to sex, age, mean duration of diabetes, actual
HbA1c percentage and HbA1c percentage in the last 5 years,
microalbuminuria, and blood pressure.
During follow-up, no statistically significant difference
was present between the 2 groups with respect to HbA1c
percentage, blood pressure, and microalbuminuria (Table 2).
In the treated group, BCVA and mean RS reduced during
follow-up, but without statistical significance (P> 0.05 at
months 3, 6, and 14). Five eyes (25%) showed disappearance
of the retinal cysts after a mean time of 3.5 0.3 months, and
the anatomic improvement persisted during the following
months (Figure 1). When compared with the control group,
these 5 eyes showed no statistically different mean BCVA
(76.78 4.1 at baseline, P¼ 0.9; 76.11 4.1 at month 3, P¼ 0.8;
76.78 4.5 atmonth 6, P¼ 0.8; 76.15 5.2 atmonth 14, P¼ 0.6)
but an improved mean RS (16.24 0.31 at baseline, P¼ 0.8;
16.24 0.49 at month 3, P¼ 0.01; 16.32 0.46 at month 6,
P< 0.001; 16.43 0.39 at month 14, P< 0.001). Two eyes (10%)
showed an increase of retinal edema during follow-up, asso-
ciated with visual loss and reduction of RS (P> 0.05). In the
remaining 13 eyes (65%), BCVA, CRT, and RS did not show
any significant change during follow-up (P> 0.05).
In the control group, no improvement of BCVA and CRT
was observed during follow-up, worsening was observed in
5 eyes (25%, P> 0.05), and stabilization was observed in the
remaining 15 eyes (75%). Mean RS showed a reduction
during follow-up (P¼ 0.08 at month 3; P< 0.001 at months 6
and 14).
No differences in BCVA, mean CRT, and stability of fix-
ation between the 2 groups were observed during follow-up
(P> 0.05), whereas a greater RS was present in the treated
group at month 14 (P¼ 0.01).
Discussion
In this prospective, interventional, controlled study, we
evaluated the effects of the orally administered combination
of flavonoids, C. asiatica, and Melilotus on diabetic CME
without macular thickening during 14 months of follow-up.
To our knowledge, no previous reports have focused on this
issue. CME without macular thickening has been recently
reported by Jun et al. in 5.6% of eyes of 653 patients affected
by different retinal pathologies.2 Among them, non-
proliferative diabetic retinopathy without significant macu-
lar edema was present in 27% of cases.
While mean BCVA, CRT and fixation stability did not
show significant differences between the 2 groups during
follow up, at 14-month follow up visit the treated group
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showed a greater RS (P¼ 0.01). Reduction of RS was sig-
nificant in the control group only, at month-6 and at month-
14 (P< 0.001). Moreover, 5 eyes in the treated group showed
a disappearance of the intraretinal cysts, which persisted
during follow up and was associated with a significant
improvement in RS at each follow up visit when compared
to control group. On the other hand, no eye in the control
group showed an anatomical improvement. Anatomic and
functional improvement in the treated group could reflect
the beneficial effects of the treatment, mostly in consider-
ation that no significant differences were observed between
the 2 groups as concerns changes of HbA1c percentage,
microalbuminuria and blood pressure during follow up.
Flavonoids have showed to improve endothelial cells func-
tion, to have an antivascular endothelial growth factor effect
and to increase release of fibrinolytic agents.3–5,11 In a pro-
spective controlled evaluation of patients with retinal vein
occlusion, Glacet-Bernard et al. showed that troxerutin
could improve visual acuity, retinal circulation times and
macular edema.12 Flavonoids act by inhibiting leukocyte
activation, rolling, adhesion, and migration.13–15 The fresh
Melilotus plant contains a glycoside (melilotoside) which
releases glucose and coumaric acid during the drying
process. From the latter 0.4%–0.9% is transformed into
coumarin. Previous studies showed that coumarin has anti-
inflammatory properties by suppressing the phosphoryla-
tion of protein kinase B.16 The beneficial effects on RS and
the disappearance of intraretinal cysts could be related to
the combination of anti-inflammatory effect and reduction
of endothelial cells permeability.
Despite the beneficial effects on RS, the treated group did
not show significant differences with the control group with
respect to BCVA and fixation stability. Visual acuity
depends on the foveal area, whereas MP tests the RS in a
larger area surrounding the fovea. Focal alterations may
affect visual acuity and light sensitivity reduction more
than diffuse edema,17,18 as they block the light from pho-
toreceptors even before establishment of a structural dam-
age to the retina. Therefore, intraretinal cystoid spaces
could determine a functional impairment even in the
absence of retinal thickening. Small anatomic changes due
to disappearance of the retinal cysts could more easily
reflect in an improvement of RS rather than in a gross
improvement of visual acuity.
A limitation of this study is the relatively small sample
size in the 2 groups, mainly because of the prospective de-
sign. On the other hand, major strengths are the prospective
nature, standardization of data collection, and length and
high rate of follow-up. In view of the unexpected functional
benefits in the treated group, this study represents a pilot
study for a much larger trial aiming to definitely address
whether a combination of flavonoids, C. asiatica, and Meli-
lotus is beneficial in preserving RS in diabetic CME without
macular thickening.
In conclusion, diabetic CME without retinal thickening
showed to affect RS in the long term, with no significant
visual and anatomic changes detected. Therefore, MP could
represent a better diagnostic tool than visual acuity alone to
detect functional changes during follow-up. This prospective
pilot study suggests a beneficial role of the orally adminis-
tered combination of flavonoids, C. asiatica, and Melilotus for
functional preservation in case of diabetic CME without
retinal thickening.
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